- SEQENS sold its Limoges Botanical Actives and IVD activities to Solabia.
- The transaction supports SEQENS' focus on Pharmaceutical Solutions and Specialty Ingredients.
- Solabia will integrate the Limoges site into its operations for personal care and life sciences.
- SEQENS continues to support the Personal Care market with a focused portfolio.
Transaction Overview
SEQENS has announced the sale of its Botanical Actives and In Vitro Diagnostics activities in Limoges, France, to Solabia. This move is part of SEQENS' strategy to concentrate on its core Pharmaceutical Solutions and Specialty Ingredients.
Strategic Alignment
The divestment allows SEQENS to focus resources on strategic priorities, while ensuring a sustainable future for the Limoges site. Solabia's expertise in botanical actives and diagnostics aligns with the site's activities.
Benefits for Limoges Facility
Integration into Solabia provides the Limoges facility with a shareholder possessing a strong scientific culture and a long-term development vision in personal care and life sciences, enabling the site to reach its full potential.
SEQENS' Ongoing Commitment
SEQENS reaffirms its commitment to the Personal Care market, continuing to support customers with a focused portfolio that includes nontraditional preservative solutions, performance ingredients, salicylic acid and derivatives, biotech-based ingredients, and custom solutions.
